BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23090696)

  • 21. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.
    Chien J; Fan JB; Bell DA; April C; Klotzle B; Ota T; Lingle WL; Gonzalez Bosquet J; Shridhar V; Hartmann LC
    Gynecol Oncol; 2009 Jul; 114(1):3-11. PubMed ID: 19410283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival.
    Choi CH; Choi JJ; Park YA; Lee YY; Song SY; Sung CO; Song T; Kim MK; Kim TJ; Lee JW; Kim HJ; Bae DS; Kim BG
    Br J Cancer; 2012 Jun; 107(1):91-9. PubMed ID: 22644307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
    Pradhan M; Risberg BA; Tropé CG; van de Rijn M; Gilks CB; Lee CH
    BMC Cancer; 2010 Sep; 10():493. PubMed ID: 20843305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
    Wong KK; Tsang YT; Deavers MT; Mok SC; Zu Z; Sun C; Malpica A; Wolf JK; Lu KH; Gershenson DM
    Am J Pathol; 2010 Oct; 177(4):1611-7. PubMed ID: 20802181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
    Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer.
    King ER; Tung CS; Tsang YT; Zu Z; Lok GT; Deavers MT; Malpica A; Wolf JK; Lu KH; Birrer MJ; Mok SC; Gershenson DM; Wong KK
    Am J Surg Pathol; 2011 Jun; 35(6):904-12. PubMed ID: 21451362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous Ovarian Cancer and Predicts Differential Therapeutic Responses.
    Hao D; Li J; Jia S; Meng Y; Zhang C; Wang L; Di LJ
    Clin Cancer Res; 2017 Dec; 23(23):7400-7411. PubMed ID: 28939742
    [No Abstract]   [Full Text] [Related]  

  • 29. Differential gene expression identifies subgroups of ovarian carcinoma.
    Skubitz AP; Pambuccian SE; Argenta PA; Skubitz KM
    Transl Res; 2006 Nov; 148(5):223-48. PubMed ID: 17145569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.
    Nam EJ; Kim S; Lee TS; Kim HJ; Lee JY; Kim SW; Kim JH; Kim YT
    Oncotarget; 2016 Oct; 7(43):70524-70534. PubMed ID: 27655640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
    Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
    Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas.
    Partheen K; Levan K; Osterberg L; Claesson I; Sundfeldt K; Horvath G
    BMC Cancer; 2009 Sep; 9():336. PubMed ID: 19775429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis of gene expression profiles among 3 epithelial ovarian tumor subtypes using cDNA and tissue microarrays].
    Zheng M; Simon R; Kononen J; Sauter G; Mihatsch MJ; Moch H
    Ai Zheng; 2004 Jul; 23(7):771-6. PubMed ID: 15248910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.
    Netinatsunthorn W; Hanprasertpong J; Dechsukhum C; Leetanaporn R; Geater A
    BMC Cancer; 2006 Apr; 6():90. PubMed ID: 16606472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
    Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
    Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer.
    Sawiris GP; Sherman-Baust CA; Becker KG; Cheadle C; Teichberg D; Morin PJ
    Cancer Res; 2002 May; 62(10):2923-8. PubMed ID: 12019173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification by cDNA microarray of genes involved in ovarian carcinogenesis.
    Ono K; Tanaka T; Tsunoda T; Kitahara O; Kihara C; Okamoto A; Ochiai K; Takagi T; Nakamura Y
    Cancer Res; 2000 Sep; 60(18):5007-11. PubMed ID: 11016619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo.
    Nagare RP; Sneha S; Krishnapriya S; Ramachandran B; Murhekar K; Vasudevan S; Shabna A; Ganesan TS
    Exp Cell Res; 2020 Jul; 392(1):112009. PubMed ID: 32305326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
    Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R
    Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene microarray analysis of lncRNA and mRNA expression profiles in patients with high‑grade ovarian serous cancer.
    Lou Y; Jiang H; Cui Z; Wang X; Wang L; Han Y
    Int J Mol Med; 2018 Jul; 42(1):91-104. PubMed ID: 29577163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.